Principal Financial Group Inc. Purchases New Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Principal Financial Group Inc. bought a new stake in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 95,961 shares of the medical instruments supplier's stock, valued at approximately $879,000. Principal Financial Group Inc. owned about 0.24% of AngioDynamics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Rhumbline Advisers increased its holdings in shares of AngioDynamics by 1.7% in the 4th quarter. Rhumbline Advisers now owns 60,479 shares of the medical instruments supplier's stock worth $554,000 after acquiring an additional 1,021 shares during the period. White Pine Capital LLC raised its stake in shares of AngioDynamics by 189.6% during the fourth quarter. White Pine Capital LLC now owns 64,033 shares of the medical instruments supplier's stock valued at $587,000 after purchasing an additional 41,925 shares in the last quarter. R Squared Ltd acquired a new stake in AngioDynamics in the fourth quarter worth about $49,000. SG Americas Securities LLC grew its position in AngioDynamics by 21.3% in the 4th quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier's stock valued at $147,000 after buying an additional 2,832 shares in the last quarter. Finally, Moody National Bank Trust Division increased its stake in AngioDynamics by 70.2% during the 4th quarter. Moody National Bank Trust Division now owns 55,780 shares of the medical instruments supplier's stock valued at $511,000 after buying an additional 23,003 shares during the period. 89.43% of the stock is currently owned by institutional investors.

Remove Ads

AngioDynamics Price Performance

Shares of AngioDynamics stock traded down $0.73 during trading on Monday, hitting $8.37. The stock had a trading volume of 769,416 shares, compared to its average volume of 752,438. The business has a fifty day moving average of $10.83 and a two-hundred day moving average of $8.59. The firm has a market cap of $338.70 million, a P/E ratio of -1.49 and a beta of 0.56. AngioDynamics, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The company had revenue of $72.90 million during the quarter, compared to analyst estimates of $70.93 million. During the same quarter last year, the firm posted ($0.05) EPS. The business's revenue for the quarter was down .1% on a year-over-year basis. As a group, research analysts forecast that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright increased their price objective on shares of AngioDynamics from $14.00 to $15.00 and gave the company a "buy" rating in a report on Friday, January 10th.

Insider Buying and Selling

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of the company's stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the sale, the senior vice president now directly owns 41,817 shares of the company's stock, valued at $514,767.27. This represents a 8.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 5.40% of the company's stock.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.